Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Imbria Pharmaceuticals is raising $80,734,932.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Gros played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Imbria Pharmaceuticals

Imbria Pharmaceuticals’ mission is to translate our understanding of cellular metabolism into innovative medicines that improve the lives of patients with limited or inadequate treatment options. The company was founded by doctors and launched by an all doctor executive team motivated by the promise of bringing new therapies to people in need. We are propelled by a deep scientific interest in cellular metabolism and the mitochondria, and are guided by both values and a code of business conduct built upon our commitment to always put the patients, families and communities we serve at the forefront of all that we do.

To learn more about Imbria Pharmaceuticals, visit http://imbria.com/

Contact:
David Gros, Chief Executive Officer
858-413-7899
https://www.linkedin.com/in/dagros/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved